Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics develops cell therapies for autoimmune diseases, with a focus on CD19-targeting CAR T approaches. The company's recurring news centers on miv-cel, also known as mivocabtagene autoleucel or KYV-101, an autologous CAR T-cell therapy candidate being studied across B-cell-driven autoimmune diseases.
Company updates commonly cover clinical data from the KYSA neuroimmunology program, including stiff person syndrome and generalized myasthenia gravis, as well as additional autoimmune indications such as multiple sclerosis and rheumatoid arthritis. Kyverna also reports business and financial results, medical-meeting presentations, board and executive appointments, and commercial leadership developments tied to its transition from clinical development toward potential product launch activity.
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
The Leerink fireside chat is scheduled for March 9, 2026 at 11:20 a.m. ET; a live webcast and a 90-day replay will be available via the company investor website, according to the company.
Kyverna Therapeutics (Nasdaq: KYTX) announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors effective Feb. 24, 2026. Emany will serve as Audit Committee Chair following Dan Spiegelman’s departure from the board. The hires add finance, capital-markets, clinical development and product-approval experience as Kyverna advances autoimmune CAR T programs toward commercialization.
The company highlighted Emany’s CFO and investment-banking background and Miller’s R&D leadership and role in Karuna’s acquisition and KarXT development.
Kyverna Therapeutics (NASDAQ: KYTX) named Mayo Pujols as Chief Technology Officer, effective February 9, 2026, succeeding Karen Walker who will consult during the transition.
Pujols brings 30+ years in cell and gene therapy manufacturing. Kyverna disclosed an inducement option for 300,000 shares vesting over four years; grant tied to the closing stock price on the grant date.
Kyverna Therapeutics (NASDAQ: KYTX) provided a corporate update and 2026 priorities on Jan 12, 2026, highlighting late‑stage progress for its CAR T candidate miv‑cel. Key items: Kyverna plans to file a BLA for stiff person syndrome (SPS) in 1H 2026 after positive registrational topline data; the first patient has enrolled in the Phase 3 portion of the gMG KYSA‑6 trial; an IND for KYV‑102 was accepted by FDA in Jan 2026; a December 2025 follow‑on offering raised approximately $105M, and cash, cash equivalents, and marketable securities were ~$279M as of Dec 31, 2025, extending runway into 2028. Christi Shaw was appointed Executive Chairperson to strengthen CAR T commercialization experience.
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 14, 2026 at 9:45 a.m. PT.
Investors can access a live audio webcast via the company's Investors page at ir.kyvernatx.com. A replay will be available on the website for 30 days after the conference.
Kyverna Therapeutics (Nasdaq: KYTX) priced an underwritten public offering of 13,333,333 common shares at $7.50 per share to raise approximately $100 million gross, before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about December 18, 2025, and Kyverna granted a 30-day option for underwriters to buy up to 1,999,999 additional shares at the public offering price less underwriting discounts and commissions.
J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities are joint book-running managers. The securities are offered under an effective Form S-3 shelf registration declared effective on April 15, 2025.
Kyverna Therapeutics (Nasdaq: KYTX) announced a proposed underwritten public offering of $100,000,000 of common stock on December 15, 2025, with a 30-day underwriter option to purchase up to an additional $15,000,000 of shares at the public offering price, less underwriting discounts and commissions.
All shares will be sold by Kyverna and the offering is being led by J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities. The offering is subject to market and other conditions and will be made pursuant to an effective Form S-3 shelf registration (File No. 333-286180); a preliminary prospectus supplement will be filed with the SEC.
Kyverna Therapeutics (Nasdaq: KYTX) announced positive topline results from the registrational Phase 2 KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome (SPS) on December 15, 2025. In 26 dosed patients at the Week 16 primary analysis, miv-cel achieved a median 46% improvement in timed 25-foot walk (T25FW) vs baseline (p=0.0002) and 81% of patients exceeded a clinically meaningful 20% T25FW improvement. All secondary endpoints showed highly significant benefits (all p<0.0001).
Safety was manageable with no high-grade CRS or ICANS; Grade 3/4 neutropenia was observed. Kyverna plans a BLA submission in 1H 2026 and will present full data at a 2026 medical conference.
Kyverna Therapeutics (Nasdaq: KYTX) will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 AM ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS).
Registration is required to receive a dial-in number and unique PIN; the event can also be accessed via live webcast. Presentation materials will be posted in the Events & Presentations section of Kyverna's investor relations website and an archived replay will be available after the call.
Kyverna Therapeutics (Nasdaq: KYTX) reported Q3 2025 results and a business update, highlighting clinical progress and financing to support late‑stage programs.
Key points: topline SPS (KYSA-8) registrational data now expected in early 2026 with a BLA submission anticipated in 1H 2026; positive interim Phase 2 gMG (KYSA-6) data showing 100% (6/6) patients with mean MG‑ADL −8.0 and QMG −7.7 at 24 weeks and no high‑grade CRS or ICANS; IND for KYV‑102 on track for Q4 2025. Financially, cash and equivalents were $171.1M as of Sept 30, 2025, and Kyverna closed a loan facility up to $150M (initial $25M drawn), supporting a cash runway into 2027.